Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates

Chad Mire, Joan B. Geisbert, Krystle N. Agans, Emily P. Thi, Amy C H Lee, Karla A. Fenton, Thomas Geisbert

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background. Convalescent serum and blood were used to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inconclusive results. During the recent 2013-2016 West African epidemic, serum/plasma from survivors of ZEBOV infection was used to treat patients in the affected countries and several repatriated patients. The effectiveness of this strategy remains unknown. Methods. Nine rhesus monkeys were experimentally infected with ZEBOV-Makona. Beginning on day 3 after exposure (at the onset of viremia), 4 animals were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as positive controls and were not treated. Surviving animals received additional treatments on days 6 and 9. Results. Both untreated control animals died on postinfection day 9. All 4 ZEBOV-Makona-infected macaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9. One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals treated with the heterologous SEBOV sera died on days 7 and 9. Conclusions. The findings suggest that convalescent sera alone is not sufficient for providing 100% protection against lethal ZEBOV infection when administered at the onset of viremia.

Original languageEnglish (US)
Pages (from-to)S367-S374
JournalJournal of Infectious Diseases
Volume214
DOIs
StatePublished - Oct 15 2016

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Passive Immunization
Primates
Democratic Republic of the Congo
Serum
Macaca
Sudan
Viremia
Infection
Macaca mulatta
Disease Outbreaks
Survivors

Keywords

  • Convalescent serum
  • Ebola virus
  • Immunotherapy
  • Post exposure treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Passive Immunotherapy : Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. / Mire, Chad; Geisbert, Joan B.; Agans, Krystle N.; Thi, Emily P.; Lee, Amy C H; Fenton, Karla A.; Geisbert, Thomas.

In: Journal of Infectious Diseases, Vol. 214, 15.10.2016, p. S367-S374.

Research output: Contribution to journalArticle

Mire, Chad ; Geisbert, Joan B. ; Agans, Krystle N. ; Thi, Emily P. ; Lee, Amy C H ; Fenton, Karla A. ; Geisbert, Thomas. / Passive Immunotherapy : Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. In: Journal of Infectious Diseases. 2016 ; Vol. 214. pp. S367-S374.
@article{e732c5f5fc144417b577aed313945549,
title = "Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates",
abstract = "Background. Convalescent serum and blood were used to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inconclusive results. During the recent 2013-2016 West African epidemic, serum/plasma from survivors of ZEBOV infection was used to treat patients in the affected countries and several repatriated patients. The effectiveness of this strategy remains unknown. Methods. Nine rhesus monkeys were experimentally infected with ZEBOV-Makona. Beginning on day 3 after exposure (at the onset of viremia), 4 animals were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as positive controls and were not treated. Surviving animals received additional treatments on days 6 and 9. Results. Both untreated control animals died on postinfection day 9. All 4 ZEBOV-Makona-infected macaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9. One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals treated with the heterologous SEBOV sera died on days 7 and 9. Conclusions. The findings suggest that convalescent sera alone is not sufficient for providing 100{\%} protection against lethal ZEBOV infection when administered at the onset of viremia.",
keywords = "Convalescent serum, Ebola virus, Immunotherapy, Post exposure treatment",
author = "Chad Mire and Geisbert, {Joan B.} and Agans, {Krystle N.} and Thi, {Emily P.} and Lee, {Amy C H} and Fenton, {Karla A.} and Thomas Geisbert",
year = "2016",
month = "10",
day = "15",
doi = "10.1093/infdis/jiw333",
language = "English (US)",
volume = "214",
pages = "S367--S374",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Passive Immunotherapy

T2 - Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Agans, Krystle N.

AU - Thi, Emily P.

AU - Lee, Amy C H

AU - Fenton, Karla A.

AU - Geisbert, Thomas

PY - 2016/10/15

Y1 - 2016/10/15

N2 - Background. Convalescent serum and blood were used to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inconclusive results. During the recent 2013-2016 West African epidemic, serum/plasma from survivors of ZEBOV infection was used to treat patients in the affected countries and several repatriated patients. The effectiveness of this strategy remains unknown. Methods. Nine rhesus monkeys were experimentally infected with ZEBOV-Makona. Beginning on day 3 after exposure (at the onset of viremia), 4 animals were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as positive controls and were not treated. Surviving animals received additional treatments on days 6 and 9. Results. Both untreated control animals died on postinfection day 9. All 4 ZEBOV-Makona-infected macaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9. One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals treated with the heterologous SEBOV sera died on days 7 and 9. Conclusions. The findings suggest that convalescent sera alone is not sufficient for providing 100% protection against lethal ZEBOV infection when administered at the onset of viremia.

AB - Background. Convalescent serum and blood were used to treat patients during outbreaks of Zaire ebolavirus (ZEBOV) infection in 1976 and 1995, with inconclusive results. During the recent 2013-2016 West African epidemic, serum/plasma from survivors of ZEBOV infection was used to treat patients in the affected countries and several repatriated patients. The effectiveness of this strategy remains unknown. Methods. Nine rhesus monkeys were experimentally infected with ZEBOV-Makona. Beginning on day 3 after exposure (at the onset of viremia), 4 animals were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in parallel with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as positive controls and were not treated. Surviving animals received additional treatments on days 6 and 9. Results. Both untreated control animals died on postinfection day 9. All 4 ZEBOV-Makona-infected macaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9. One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals treated with the heterologous SEBOV sera died on days 7 and 9. Conclusions. The findings suggest that convalescent sera alone is not sufficient for providing 100% protection against lethal ZEBOV infection when administered at the onset of viremia.

KW - Convalescent serum

KW - Ebola virus

KW - Immunotherapy

KW - Post exposure treatment

UR - http://www.scopus.com/inward/record.url?scp=84990982238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990982238&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw333

DO - 10.1093/infdis/jiw333

M3 - Article

C2 - 27571900

AN - SCOPUS:84990982238

VL - 214

SP - S367-S374

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -